LogicBio Therapeutics (OTCMKTS:LOGC) Sets New 1-Year High – Still a Buy?

LogicBio Therapeutics, Inc. (OTCMKTS:LOGC) shares hit a new 52-week high during trading on Tuesday. The stock traded as high as $15.45 and last traded at $15.3948, with a volume of 24,675 shares changing hands. The stock had previously closed at $15.29.

LogicBio Therapeutics Price Performance

The firm has a market cap of $701.97 million, a price-to-earnings ratio of -21.03 and a beta of 2.04. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.24 and a current ratio of 1.87. The stock’s 50 day simple moving average is $14.28 and its 200-day simple moving average is $10.08.

LogicBio Therapeutics (OTCMKTS:LOGC) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.10). The firm had revenue of $33.60 million for the quarter, compared to analyst estimates of $33.60 million.

LogicBio Therapeutics Company Profile

LogicBio Therapeutics, Inc was a clinical-stage genetic medicine company focused on developing therapies for patients with serious genetic and metabolic diseases. The company’s research centered on genetic medicine technologies designed to address the underlying causes of disease rather than treat symptoms alone.

LogicBio’s principal platform, GeneRide, was developed to enable the targeted insertion of therapeutic genes into the genome. The company also pursued GeneWare, a platform intended to support gene-editing applications.